oncerned about patent rights, two large pharmaceutical industry trade groups have asked U.S. trade officials to place the European Union on a so-called watch list of countries that, arguably, do not sufficiently protect intellectual property rights.

The move comes in response to a pair of European Commission reviews. One concerns incentives for patents and their impact on innovation and access to medicines. The other might rework “supplementary protection certificates,” which are essentially patent extensions, by offering waivers to third parties to make and export patent-protected drugs.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.